Abstract
Chagas disease is a Neglected Tropical Disease (NTD), and although it is endemic in Latin America, it affects around 6-7 million people worldwide. The treatment of Chagas disease is based on benznidazole and nifurtimox, which are the only available drugs. However, they are not effective during the chronic phase and cause several side effects. Furthermore, BZ promotes cure in 80% of the patients in the acute phase, but the cure rate drops to 20% in adults in the chronic phase of the disease. In this review, we present several studies published in the last six years, which describe the antiparasitic potential of distinct drugs, from the synthesis of new compounds, aiming to target the parasite, as well as the repositioning and the combination of drugs. We highlight several compounds that have shown equivalency or superiority to BZ, which means that they should be further studied, either in vitro or in vivo. Furthermore, we highlight the differences in the effects of BZ on the same strain of T. cruzi, which might be related to methodological differences, such as parasite and cell ratios, host cell type, and the time of adding the drug. In addition, we discussed the wide variety of strains and also the cell types used as host cells, making it difficult to compare the trypanocidal effect of the compounds.
Keywords: Benznidazole, chagas disease, chemotherapy, drug design, synthesis, Trypanosoma cruzi.
Current Pharmaceutical Design
Title:Chagas Disease Chemotherapy: What Do We Know So Far?
Volume: 27 Issue: 38
Author(s): Aline A. Zuma*Wanderley de Souza
Affiliation:
- Laboratorio de Ultraestrutura Celular Hertha Meyer, Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro; Av. Carlos Chagas Filho, 373, Centro de Ciencias da Saude, Cidade Universitaria, Ilha do Fundao, 21491-590, Rio de Janeiro, RJ,Brazil
Keywords: Benznidazole, chagas disease, chemotherapy, drug design, synthesis, Trypanosoma cruzi.
Abstract: Chagas disease is a Neglected Tropical Disease (NTD), and although it is endemic in Latin America, it affects around 6-7 million people worldwide. The treatment of Chagas disease is based on benznidazole and nifurtimox, which are the only available drugs. However, they are not effective during the chronic phase and cause several side effects. Furthermore, BZ promotes cure in 80% of the patients in the acute phase, but the cure rate drops to 20% in adults in the chronic phase of the disease. In this review, we present several studies published in the last six years, which describe the antiparasitic potential of distinct drugs, from the synthesis of new compounds, aiming to target the parasite, as well as the repositioning and the combination of drugs. We highlight several compounds that have shown equivalency or superiority to BZ, which means that they should be further studied, either in vitro or in vivo. Furthermore, we highlight the differences in the effects of BZ on the same strain of T. cruzi, which might be related to methodological differences, such as parasite and cell ratios, host cell type, and the time of adding the drug. In addition, we discussed the wide variety of strains and also the cell types used as host cells, making it difficult to compare the trypanocidal effect of the compounds.
Export Options
About this article
Cite this article as:
Zuma A. Aline*, de Souza Wanderley , Chagas Disease Chemotherapy: What Do We Know So Far?, Current Pharmaceutical Design 2021; 27 (38) . https://dx.doi.org/10.2174/1381612827666210216152654
DOI https://dx.doi.org/10.2174/1381612827666210216152654 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes
Current Diabetes Reviews How to Recognize Epicardial Origin of Ventricular Tachycardias?
Current Cardiology Reviews Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Acetylome Regulation by Sirtuins in the Brain: From Normal Physiology to Aging and Pathology
Current Pharmaceutical Design Relationship Between Hypertension and Atherosclerosis: From a Viewpoint of the Most Potent Vasoconstrictor Human Urotensin II
Current Hypertension Reviews Targeting Prenylated RAS Modifying Enzymes in Cancer Cells
Current Signal Transduction Therapy Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment
Current Topics in Medicinal Chemistry Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry Invasive and Noninvasive Assessment of Exercise-induced Ischemic Diastolic Response Using Pressure Transducers
Current Cardiology Reviews Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Mitochondria, Cellular Stress Resistance, Somatic Cell Depletion and Lifespan
Current Aging Science Molecular Basis of Antiretroviral Drugs-Associated Long-Term Toxicity: How Bad can Good Drugs Be?
Current Medicinal Chemistry - Anti-Infective Agents Novel Agents Targeting Nitric Oxide
Current Vascular Pharmacology The Role of microRNAs in Cardiovascular Disease
Current Medicinal Chemistry Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews Tackling Cardiovascular Risk: New Evidence from Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Green Tea Attenuates Cardiovascular Remodeling and Metabolic Symptoms in High Carbohydrate-Fed Rats
Current Pharmaceutical Biotechnology Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Therapeutic Potential and Mechanisms of Action of Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome
Current Stem Cell Research & Therapy Role of Pharmacotherapy in Cardiac Ion Channelopathies
Current Vascular Pharmacology